253 related articles for article (PubMed ID: 12698302)
1. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
Holstein A; Plaschke A; Hammer C; Egberts EH
Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302
[TBL] [Abstract][Full Text] [Related]
2. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.
Holstein A; Plaschke A; Egberts EH
Diabetes Metab Res Rev; 2001; 17(6):467-73. PubMed ID: 11757083
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
4. Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy.
Holstein A; Plaschke A; Hammer C; Ptak M; Kuhn J; Kratzsch C; Diekmann J; Kleesiek K; Maurer HH; Egberts EH
Eur J Clin Pharmacol; 2003 Dec; 59(10):747-54. PubMed ID: 14634699
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R
Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
[TBL] [Abstract][Full Text] [Related]
6. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced severe hypoglycaemia in Type 2 diabetic patients aged 80 years or older.
Greco D; Angileri G
Diabetes Nutr Metab; 2004 Feb; 17(1):23-6. PubMed ID: 15163121
[TBL] [Abstract][Full Text] [Related]
8. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
9. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
Gallwitz B; Rosenstock J; Patel S; von Eynatten M; Hehnke U; Mehlburger L; Dugi KA; Woerle HJ
Diabetes Obes Metab; 2015 Mar; 17(3):276-84. PubMed ID: 25425502
[TBL] [Abstract][Full Text] [Related]
10. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD; Balfour JA
Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
[TBL] [Abstract][Full Text] [Related]
11. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
Dills DG; Schneider J
Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977
[TBL] [Abstract][Full Text] [Related]
13. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
Holstein A; Hammer C; Hahn M; Kulamadayil NS; Kovacs P
Expert Opin Drug Saf; 2010 Sep; 9(5):675-81. PubMed ID: 20553106
[TBL] [Abstract][Full Text] [Related]
14. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
Holstein A; Hahn M; Stumvoll M; Kovacs P
Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
[TBL] [Abstract][Full Text] [Related]
15. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance.
Charpentier G; Fleury F; Dubroca I; Vaur L; Clerson P
Diabetes Metab; 2005 Apr; 31(2):189-95. PubMed ID: 15959425
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants in GCKR, GIPR, ADCY5 and VPS13C and the risk of severe sulfonylurea-induced hypoglycaemia in patients with type 2 diabetes.
Holstein JD; Patzer O; Körner A; Stumvoll M; Kovacs P; Holstein A
Exp Clin Endocrinol Diabetes; 2013 Jan; 121(1):54-7. PubMed ID: 22956255
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz M; Martínez-Abundis E;
Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
[TBL] [Abstract][Full Text] [Related]
18. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
19. Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
Ali Z; Daniyal M; S I I; Usmanghani K; Naveed S
Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1443-9. PubMed ID: 27592478
[TBL] [Abstract][Full Text] [Related]
20. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
